尼妥珠单抗与贝伐珠单抗联合同步放化疗治疗局部晚期宫颈癌的疗效及不良反应对比研究

doi:10.11904/j.issn.1002-3070.2023.05.005

实用肿瘤学杂志 ›› 2023, Vol. 37 ›› Issue (5): 416-421.doi: 10.11904/j.issn.1002-3070.2023.05.005

尼妥珠单抗与贝伐珠单抗联合同步放化疗治疗局部晚期宫颈癌的疗效及不良反应对比研究

薛良方¹, 王欣舒², 张云艳¹, 成海燕¹, 靳红¹, 王耀先¹, 杨珊珊¹, 李奇¹

1.哈尔滨医科大学附属肿瘤医院妇放科(哈尔滨 150081);
2.南通大学医学部

收稿日期:2022-10-17 修回日期:2023-02-14 出版日期:2023-10-28 发布日期:2024-03-18
通讯作者: 李奇,E-mail:liqi@ems.hrbmu.edu.cn
作者简介:薛良方,女,(1998-),硕士研究生,从事宫颈癌基础及临床的研究。
基金资助:
哈尔滨医科大学附属肿瘤医院海燕基金项目(编号:JJZD2021-16)

A comparative study on the efficacy and adverse reactions of nituzumab and bevacizumab combined with synchronous radiotherapy and chemotherapy in the treatment of locally advanced cervical cancer

XUE Liangfang¹, WANG Xinshu², ZHANG Yunyan¹, CHENG Haiyan¹, JIN Hong¹, WANG Yaoxian¹, YANG Shanshan¹, LI Qi¹

1. Department of Gynecologic Radiotherapy,Harbin Medical University Cancer Hospital,Harbin 150081,China;
2. Department of Medicine,Nantong University

Received:2022-10-17 Revised:2023-02-14 Online:2023-10-28 Published:2024-03-18

摘要/Abstract

摘要： 目的比较尼妥珠单抗联合同步放化疗与贝伐珠单抗联合同步放化疗治疗局部晚期宫颈癌的近期疗效及不良反应。方法收集2020年9月1日—2021年12月31日病理类型为鳞状细胞癌的100例局晚期宫颈癌患者,分为对照组(同步放化疗组)、尼妥组(尼妥珠单抗联合同步放化疗组)与贝伐组(贝伐珠单抗联合同步放化疗组)。比较三组患者的近期治疗总有效率、治疗前后肿瘤体积的变化、治疗前后血清鳞状细胞癌抗原(SCC)水平及治疗后不良反应。结果尼妥组、贝伐组与对照组的近期治疗总有效率分别为90.3%、87.2%及60.0%,尼妥组和贝伐组治疗总有效率均显著高于对照组,差异均有统计学意义(P＜0.001),尼妥组与贝伐组治疗总有效率无统计学差异(P＞0.05);尼妥组与贝伐组治疗后肿瘤体积缩小程度以及SCC降低的程度均高于对照组(P＜0.05),两组间无统计学差异(P＞0.05)。贝伐组高血压发生率为33.4%,明显高于对照组(10.0%)和尼妥组(12.9%)(P＜0.05),尼妥组与对照组高血压发生率无统计学差异(P＞0.05);三组除高血压外的不良反应发生率均无统计学差异(P＞0.05)。结论尼妥珠单抗联合同步放化疗和贝伐珠单抗联合同步放化疗均可以提高局部晚期宫颈癌的近期疗效,有效缩小肿瘤体积和抑制肿瘤标志物表达,效果均优于单纯同步放化疗。尼妥珠单抗相较于贝伐珠单抗,不良反应更少,对于局部晚期宫颈癌患者来说,尼妥珠单联合同步放化疗安全性更为可靠。

关键词: 宫颈癌, 局部晚期, 尼妥珠单抗, 贝伐珠单抗, 同步放化疗

Abstract: Objective The objective of this study was to compare the short-term efficacy and adverse reactions of nituzumab combined with synchronous radiotherapy and chemotherapy and bevacizumab combined with synchronous radiotherapy and chemotherapy in the treatment of locally advanced cervical cancer. Methods A total of 100 locally advanced cervical cancer patients with pathological type of squamous cell carcinoma were collected from 1 September 2020 to 31 December 2021.They were divided into a control group(synchronous radiotherapy and chemotherapy group),a nituzumab group(nituzumab combined synchronous radiotherapy group)and a bevacizumab group(bevacizumab combined synchronous radiotherapy and chemotherapy group).The total effective rate of short-term treatment,changes in tumor volume before and after treatment,serum squamous cell carcinoma antigen(SCC)levels before and after treatment,and adverse reactions after treatment were compared among patients of the three groups. Results The short-term total effective rates of the Nitro group,Bevar group and control group were 90.3%,87.2% and 60.0%,respectively.The total effective rates of the Nitro and Bevar groups were significantly higher than those of the control group,and the differences were statistically significant(P＜0.001).There was no statistically significant difference in the total effective rates of the Nitro and Bevar groups(P＞0.05);The degree of tumor volume reduction and SCC reduction in the Nituo group and Bevac group after treatment was higher than those in the control group(P＜0.05),and there was no statistically significant difference between the two groups(P＞0.05).The incidence of hypertension in the Bevar group was 33.4%,significantly higher than that in the control group(10.0%)and the Nitro group(12.9%)(P＜0.05).There was no statistically significant difference in the incidence of hypertension between the Nito group and the control group(P＞0.05);There was no statistically significant difference in the incidence of adverse reactions among the three groups except hypertension(P＞0.05). Conclusion Nituzumab combined with synchronous radiotherapy and chemotherapy,as well as bevacizumab combined with synchronous radiotherapy and chemotherapy,can improve the short-term efficacy of locally advanced cervical cancer,effectively reduce tumor volume and inhibit the expression of tumor markers,both of which are superior to synchronous radiotherapy and chemotherapy alone.Compared to bevacizumab,nituzumab has fewer adverse reactions.For patients with locally advanced cervical cancer,the combination of nituzumab and concurrent radiotherapy and chemotherapy is more reliable in terms of safety.

Key words: Cervical cancer, Locally advanced, Nituzumab, Bevacizumab, Synchronous radiotherapy and chemotherapy

中图分类号:

R711.74

薛良方, 王欣舒, 张云艳, 成海燕, 靳红, 王耀先, 杨珊珊, 李奇. 尼妥珠单抗与贝伐珠单抗联合同步放化疗治疗局部晚期宫颈癌的疗效及不良反应对比研究[J]. 实用肿瘤学杂志, 2023, 37(5): 416-421.

XUE Liangfang, WANG Xinshu, ZHANG Yunyan, CHENG Haiyan, JIN Hong, WANG Yaoxian, YANG Shanshan, LI Qi. A comparative study on the efficacy and adverse reactions of nituzumab and bevacizumab combined with synchronous radiotherapy and chemotherapy in the treatment of locally advanced cervical cancer[J]. Journal of Practical Oncology, 2023, 37(5): 416-421.

0
/ / 推荐

导出引用管理器 EndNote|Reference Manager|ProCite|BibTeX|RefWorks

链接本文: http://journal09.magtechjournal.com/Jwk3_syzlxzz/CN/10.11904/j.issn.1002-3070.2023.05.005

http://journal09.magtechjournal.com/Jwk3_syzlxzz/CN/Y2023/V37/I5/416

参考文献

1 Choi S,Ismail A,Pappas-Gogos G,et al.HPV and cervical cancer:A review of epidemiology and screening uptake in the UK[J].Pathogens,2023,12(2):298.
2 Sung H,Ferlay J,Siegel RL,et al.Global cancer statistics 2020:GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J].CA Cancer J Clin,2021,71(3):209-249.
3 Zhang Y,Fan S,Shan M,et al.Propensity score matching analysis to comparing cisplatin versus nedaplatin based doublet agent concurrent chemoradiotherapy for locally advanced cervical cancer[J].Scientific Reports,2023,13(1):9352.
4 Monk BJ,Tan DSP,Pujade-Lauraine E.Proportions andincidence of locallyadvanced cervical cancer.a globalsystematic literature review[J].Int J Gynecol Cancer,2022,32(12)1531-1539.
5 杨淑莉,任继凤,刘洁清,等.局部晚期宫颈癌综合治疗前沿进展[J].中华转移性肿瘤杂志,2022,5(4):362-366.
6 彭琛,谢印通,张昕,等.宫颈癌维持治疗研究进展[J].国际肿瘤学杂志,2022,49(7):430-435.
7 李欣,胡莉钧,于静萍.重组人血管内皮抑制素联合放化疗治疗宫颈癌研究进展[J].中华放射肿瘤学杂志,2023,32(1):75-80.
8 高颜凤,温坚,庄茜茹.贝伐珠单抗联合同步放化疗治疗局部晚期宫颈癌的效果观察[J].中国肿瘤临床与康复,2022,29(6):713-716.
9 Garcia J,Hurwitz H I,Sandler AB,et al.Bevacizumab(Avastin^®)in cancer treatment:A review of 15 years of clinical experience and future outlook[J].Cancer Treat Rev,2020,86:102017.
10 Lalchandani UR,Sahai V,Hersberger K,et al.A radiologist's guide to response evaluation criteria in solid tumors[J].Curr Probl Diagn Radiol,2019,48(6):576-585.
11 Tony V,Sathyamurthy A,Ramireddy JK,et al.Role of squamous cell carcinoma antigen in prognostication,monitoring of treatment response,and surveillance of locally advanced cervical carcinoma[J].J Cancer Res Ther,2023,19(5):1236-1240.
12 Benito V,Lubrano A,Pérez-Regadera J F,et al.Postreatment squamous cell carcinoma antigen as a survival prognostic factor in patients with locally advanced cervical cancer.A Spanish multicenter study.The SEGO Spain-GOG group[J].Gynecologic Oncology,2021,162(2):407-412.
13 杨华,魏丽春,张莹,等.联合贝伐珠单抗新辅助化疗＋同步放化疗治疗局部晚期巨块型宫颈癌的初步临床研究[J].中华放射肿瘤学杂志,2021,30(4):372-375.
14 Hemmat N,Mokhtarzadeh A,Aghazadeh M,et al.Role of microRNAs in epidermal growth factor receptor signaling pathway in cervical cancer[J].Mol Biol Rep,2020,47:4553-4568.
15 Zhang L,Jiang Y,Jiang P,et al.Efficacy and safety of nimotuzumab combined with chemoradiotherapy in the treatment of locally advanced cervical cancer[J].Ann Transl Med 2022,10(24):1322.
16 陈杰,曹元杰,朱莉,等.尼妥珠单抗联合同步放化疗治疗局部晚期宫颈癌的临床观察[J].中华医学杂志,2021,101(8):597-601.
17 Li M,Kroetz DL.Bevacizumab-induced hypertension:Clinical presentation and molecular understanding[J].Pharmacol Ther,2018,182:152-160.
18 Hatanaka T,Kakizaki S,Hiraoka A,et al.Comparative efficacy and safety of atezolizumab and bevacizumab between hepatocellular carcinoma patients with viral and non-viral infection:A Japanese multicenter observational study[J].Cancer Med,2023,12(5):5293-5303.
19 Tay F,Buyukkor M,Ates O.Efficacy and safety of combined chemotherapy regimens with bevacizumab in platinum-sensitive ovarian cancers[J].J Coll Physicians Surg Pak,2023,33(9):1006-1011.
20 Wichelmann TA,Abdulmujeeb S,Ehrenpreis ED.Bevacizumab and gastrointestinal perforations:a review from the FDA Adverse Event Reporting System(FAERS)database[J].Aliment Pharmacol Ther 2021,54(10):1290-1297.

[1]	闵智乾, 靳荣辉, 陈丽宏, 雷晓燕, 张鑫, 张彬, 于娇, 蔺莉莉, 陈小龙. 多模态MRI评价ⅠB1-ⅡA2期宫颈癌宫旁浸润的应用研究[J]. 实用肿瘤学杂志, 2022, 36(5): 424-428.
[2]	徐慧芳, 刘茵, 赵冬梅, 罗艳林, 陈佩佩, 郭珍, 贾漫漫, 郑黎阳, 张璐瑶, 李梦洁, 张韶凯. 新型国产杂交捕获HPV检测技术在ASC-US人群分流中的应用效果评价[J]. 实用肿瘤学杂志, 2022, 36(2): 133-136.
[3]	张艺艺, 李奇, 刘旭, 王亚楠, 邹沅杰, 周慧慧, 徐春燕, 苏升琦, 葛鑫, 王铜. 宫颈癌患者五年生存及影响因素分析[J]. 实用肿瘤学杂志, 2022, 36(1): 7-13.
[4]	王丽娜, 王乐, 靳红, 李奇, 成海燕. UBQLN1在宫颈癌中的表达及其对预后的影响[J]. 实用肿瘤学杂志, 2021, 35(6): 506-510.
[5]	姚丽萍, 王宏宗, 丁高恒, 刘玉琴. 2009—2015年甘肃省肿瘤登记地区宫颈癌流行特征及变化趋势分析[J]. 实用肿瘤学杂志, 2021, 35(3): 224-230.
[6]	胡海, 黎杰, 王培, 唐斌, 王先良, 杨强. 宫颈癌后装治疗中基于U-net的自动施源器分割[J]. 实用肿瘤学杂志, 2021, 35(3): 248-253.
[7]	秦伟, 何义富, 常娜, 钱立庭, 黄大兵, 崔亚云. 局部晚期宫颈癌放射治疗对直肠功能影响的研究进展[J]. 实用肿瘤学杂志, 2021, 35(2): 170-173.
[8]	任思颖,秦明芳,陈杨,石青萍,成会荣,高娇,文洪梅. 云南省肿瘤登记地区2011—2015年宫颈癌发病和死亡特征及时间趋势[J]. 实用肿瘤学杂志, 2021, 35(1): 13-17.
[9]	卢江岳, 张建鑫, 葛晓峰. 鼻咽癌同步推量同步放化疗与常规分割后缩野同步放化疗的疗效及毒性反应对比分析[J]. 实用肿瘤学杂志, 2020, 34(5): 440-445.
[10]	李静, 王玉霞, 陈杰. 长链非编码RNA HOTAIR在宫颈癌中的相关研究进展[J]. 实用肿瘤学杂志, 2020, 34(4): 368-371.
[11]	罗丽芳, 刘运铎, 关玥, 陈秀玮. 基于槲皮素标记的金属有机框架放疗联合阿霉素诱导宫颈癌HeLa细胞凋亡的研究[J]. 实用肿瘤学杂志, 2020, 34(3): 203-207.
[12]	秦凯, 程熠, 袁响林, 简丹妮, 张菁, 黄乐. 超声膀胱容量监测技术在宫颈癌术后调强放疗中的应用价值[J]. 实用肿瘤学杂志, 2020, 34(3): 232-236.
[13]	杨东明, 卢庆刚. “半野”三维适形放疗、固定野静态调强放疗和容积旋转调强放疗在中晚期宫颈癌治疗上的剂量学比较[J]. 实用肿瘤学杂志, 2020, 34(3): 244-248.
[14]	王棹, 冯越, 邢丽楠, 张云艳. PLR与恶性肿瘤同步放化疗预后的研究进展[J]. 实用肿瘤学杂志, 2020, 34(3): 271-275.
[15]	曹宁, 夏百荣, 娄阁. HPV蛋白、miRNAs和外泌体在宫颈癌炎症作用中的研究进展[J]. 实用肿瘤学杂志, 2020, 34(3): 282-285.

尼妥珠单抗与贝伐珠单抗联合同步放化疗治疗局部晚期宫颈癌的疗效及不良反应对比研究

A comparative study on the efficacy and adverse reactions of nituzumab and bevacizumab combined with synchronous radiotherapy and chemotherapy in the treatment of locally advanced cervical cancer

PDF

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价